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Previously, renal cell carcinoma tissues were reported to display a marked reduction of components of the respiratory chain. To
elucidate a possible relationship between tumourigenesis and alterations of oxidative phosphorylation, we screened for mutations of
the mitochondrial DNA (mtDNA) in renal carcinoma tissues and patient-matched normal kidney cortex. Seven of the 15 samples
investigated revealed at least one somatic heteroplasmic mutation as determined by denaturating HPLC analysis (DHPLC). No
homoplasmic somatic mutations were observed. Actually, half of the mutations presented a level of heteroplasmy below 25%, which
could be easily overlooked by automated sequence analysis. The somatic mutations included four known D-loop mutations, four so
far unreported mutations in ribosomal genes, one synonymous change in the ND4 gene and four nonsynonymous base changes in
the ND2, COI, ND5 and ND4L genes. One renal cell carcinoma tissue showed a somatic A3243G mutation, which is a known
frequent cause of MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, stroke-like episode) and specific
compensatory alterations of enzyme activities of the respiratory chain in the tumour tissue. No difference between histopathology
and clinical progression compared to the other tumour tissues was observed. In conclusion, the low abundance as well as the
frequently observed low level of heteroplasmy of somatic mtDNA mutations indicates that the decreased aerobic energy capacity in
tumour tissue seems to be mediated by a general nuclear regulated mechanism.
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Renal cell carcinoma is the most common malignancy arising in
the adult kidney. Already five decades ago it was shown that the
vast majority of tumours display a high rate of glycolysis under
aerobic conditions (Warburg, 1956). Accordingly, in renal cell
carcinomas, an increase of proteins involved in major steps of the
glycolytic pathway and a decrease of the gluconeogenic reactions
was observed (Faure Vigny et al, 1996; Unwin et al, 2003).
Furthermore, a depletion of the activity of several mitochondrial
enzymes was demonstrated (Faure Vigny et al, 1996; Unwin et al,
2003; Meierhofer et al, 2004). Human solid tumours endure
profound hypoxia, which indicates that adaptation to hypoxic
conditions is a crucial step in tumour progression. Recently, it was
postulated that deficiency of the von Hippel Lindau (VHL) protein,
which is observed in most renal carcinomas, could be one of the
factors responsible for downregulation of the biogenesis of
complexes of the oxidative phosphorylation (OXPHOS) (Shiao
et al, 2000; Hervouet et al, 2005).
Since some subunits of the OXPHOS are encoded by mitochon-
drial DNA (mtDNA), alterations of mtDNA may influence
OXPHOS activity. Mitochondrial DNA has a high mutation rate
due to the damage produced by free radicals, the lack of protective
action by histones and the limited capacity of repair of the mtDNA
(Brown et al, 1979; Pettepher et al, 1991). The mutation rate
of mtDNA has been reported to be as much as two orders of
magnitude greater than that of nuclear DNA (Khrapko et al, 1997).
A mutation in mtDNA expands either partially (heteroplasmy) or
totally replaces all mtDNA (homoplasmy). However, it is still
unclear how mutated mtDNA expands in cells.
Recently, a high incidence of specific mtDNA alterations has
been reported for gastric (Maximo et al, 2001; Wu et al, 2005),
prostate (Jeronimo et al, 2001; Petros et al, 2005), pancreatic
(Jones et al, 2001), skin (Girald-Rosa et al, 2005), colorectal
(Polyak et al, 1998; Hibi et al, 2001a; Lievre et al, 2005), urinary
bladder (Fliss et al, 2000), thyroid (Yeh et al, 2000), oesophageal
(Hibi et al, 2001b; Kumimoto et al, 2004), liver (Nishikawa et al,
2001), breast (Richard et al, 2000; Tan et al, 2002; Zhu et al, 2005),
uterine cancers (Pejovic et al, 2004) as well as chromophobe renal
cell carcinoma (Nagy et al, 2002). Of all mtDNA mutations
reported in cancer tissues, only a few are known to be of
pathological relevance as shown for patients with disorders of
the mitochondrial energy metabolism. For example, a G5521A
mutation, which is known to cause a late onset mitochondrial
myopathy (Silvestri et al, 1998), was detected in a lung cancer
tissue (Fliss et al, 2000). A mutation (G13708A) reported in
patients with Leber’s hereditary optic neuropathy (LOHN) (Brown
et al, 1992) was found in a breast cancer tissue (Parrella et al, 2001)
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sand a mutation typical for mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes (MELAS) was detected
in a colon cancer sample (Lorenc et al, 2003). As would be
anticipated, these patients, who all were carrying only tumour-
specific pathogenic mtDNA mutations, did not show clinical
signs of mtDNA-related disease. Recently, it was shown that
the introduction of a pathogenic mtDNA mutations, for example,
in the mitochondrial-encoded ATPase 6 gene (MTATP6), can
lead to declined respiration and accelerated growth of tumour
cells via inhibition of apoptosis (Petros et al, 2005; Shidara et al,
2005).
To determine whether the downregulation of the enzyme
activities reported in renal carcinoma is associated with mtDNA
mutations, we screened the entire mtDNA of 15 paired tumour and
the corresponding normal kidney samples by denaturating HPLC
analysis (DHPLC) analysis. Occurrence and type of somatic
mtDNA mutations were compared to the enzymatic activity of
respiratory chain complexes.
MATERIALS AND METHODS
Patients
Tumour and the corresponding healthy cortex tissue from 15
patients were obtained by nephrectomy at the Department of
Urology, Salzburg as previously reported (Meierhofer et al, 2004).
The tumour classification was performed according to Storkel et al
(1997). DNA was isolated by proteinase K digestion followed by
phenol/chloroform extraction.
PCR amplification of entire mitochondrial genome and
mutation analysis
The whole human mtDNA of all 15 patients was amplified using
48 overlapping PCR fragments. Mutation detection by DHPLC
was performed as reported previously (Meierhofer et al, 2005).
As estimated from the areas under the peaks of the DHPLC
chromatogram, the degree of heteroplasmy was divided into lower
25% (o25%), between 25 and 75% (25–75%) and over 75%
(475%). All samples showing a homo- and heteroduplex peak of
the same extent in DHPLC analysis were sequenced directly.
Heteroplasmic peaks lower than the homoplasmic peak were
manually collected and reamplified as previously reported
(Meierhofer et al, 2005).
Mutations were analysed with the Beckman software investi-
gator (Fullerton, CA, USA). Exact positions of mutations and
amino-acid changes were defined with the mitoAnalyser tool
(MitoAnalyzer, 2000), using the mtDNA genbank sequence
J01415.1 as reference.
Determination of mutational load of the A3243G mutation
A PCR fragment was amplified with the following primers:
forward, 50-TCCCTGTACGAAAGGACAAGA-30; reverse, 50-AGGA
GTAGGAGGTTGGCCAT-30 and with cycling and PCR conditions
as reported previously (Meierhofer et al, 2005). The last PCR cycle
was followed by a denaturating and reannealing step. Restriction
digestion with HaeIII, which digests only the mutation-specific
restriction side 3243G and one control restriction side on each side
of the PCR fragment, was performed. The percentage of mutational
load was detected by densitometry of ethidium-bromide-stained
agarose gels (Uziel et al, 1997; van den Bosch et al, 2004).
Enzyme measurements
The following enzyme activities: citrate synthase, complex II,
complex IV and oligomycin-sensitive ATPase activity of complex
V were determined and reported previously (Meierhofer et al,
2004). In addition, complex I activity was measured according to
Rustin et al (1994).
Western blot analysis of the VHL tumour suppressor
protein
After separation of the 600g homogenate (Meierhofer et al, 2004),
18mg protein per lane were loaded on a 10% polyacrylamide gel
and Western blot analysis was performed according to Berger et al
(2003). The following antibodies were used: mouse monoclonal
antibody against VHL protein (Cat# 556347; BD Bioscience, Palo
Alto, CA, USA; 1mg/ml), alkaline phosphatase-conjugated rabbit
anti-mouse immunoglobulins (Dako, Golstrup, Denmark; 1:5000).
RESULTS
MtDNA mutations
The mutation screening of the entire mtDNA of 15 primary renal
carcinoma and matched control kidney cortex tissues was carried
out by DHPLC analysis. Five matched tumour/kidney pairs showed
one to two heteroplasmic mutations (six D-loop, one 16s rRNA
and one COI) of the mtDNA with no difference of the degree of
heteroplasmy in the two tissues (Table 1). Interestingly, in two
patients, a shift in heteroplasmy from the kidney to the
corresponding tumour tissue was observed (cases 11, 12: Table 1;
Figure 1). Loss of low-level heteroplasmy present in normal cortex
tissue was observed in cases 4 (310 C insertion; A8483G) and 14
(T72C). Only three conventional renal carcinomas with grades 1, 2
and 4 carried neither a somatic nor a heteroplasmic mtDNA
mutation.
Table 1 Nonsomatic heteroplasmies in matched tissue pairs
Case Tumour type Grade Nucleotide position Heteroplasmy
a in kidney/tumour (%) Gene Amino acid Notes
6 Papillary RC 2 A16206G 475 D-loop d
6 C16348T 475 D-loop d
7 Sarkomatoid RC 4 A16206G 25–75 D-loop d
7 C16348T 25–75 D-loop d
11 Conv. RC
b 3 T16092C from 40 to 495 D-loop c
12 Conv. RC 2 T8750C from 50 to 80 ATP6 L75S d
13 Conv. RC 1/2 T1809C 475 16S rRNA d
13 G6260A 25–75 COI syn c
14 Papillary RC 1 G75A 25–75 D-loop c
15 Conv. RC 1 T16093C 25–75 D-loop c
aEstimated by denaturating HPLC analysis.
bConv.¼conventional; RC¼renal carcinoma; syn¼synonymous. c¼Previously reported polymorphism (MITOMAP database).
d¼Novel mutation.
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sIn total, 14 types of somatic genetic mutations were detected in
seven patients (Table 2). No somatic homoplasmic mutations were
detected in any of these 15 renal carcinoma tissues. Notably, the
level of heteroplasmy of somatic mutations was frequently below
25% (Table 2), whereas all nonsomatic heteroplasmies were above
25% (Table 1).
The somatic mutations included four known D-loop mutations,
four so far unreported mutations in ribosomal genes, one
synonymous change in the ND4 gene and four nonsynonymous
base changes in the ND2, COI, ND5 and ND4L genes (Table 2).
Interestingly, in one tumour tissue, the tRNA
LEU(UUR) gene
revealed a A to G transition at position 3243, which is a known
frequent cause of MELAS syndrome (Figure 2). Restriction
digestion with HaeIII of the PCR fragment containing the
A3243G mutation revealed an 89% mutational load (Figure 2F).
The corresponding kidney tissue was unaffected.
Furthermore, the known MELAS suppresser G12300A mutation
(El Meziane et al, 1998) was not present in the tumour sample with
the A3243G mutation.
Enzyme activities
Biochemical analysis of OXPHOS and Krebs-cycle enzyme
activities of 37 renal carcinoma tissues were reported in our
previous study (Meierhofer et al, 2004), which included the 15
patients presented here (Table 3). A total of 14 renal carcinoma
tumour tissues, investigated in this study, showed a depletion of
the mtDNA content (46%) combined with a decreased activity
of complex I (16%), complex II (23%), complex IV (29%),
oligomycin-sensitive ATPase activity of complex V (25%) and
citrate synthase (72%) compared to matched normal cortex tissues
(Table 3) (Meierhofer et al, 2004).
This is in clear contrast to the tumour tissue with the A3243G
mutation, which showed an upregulation of the mtDNA content
(170%) and increased enzyme activities of complex II (138%),
oligomycin-sensitive ATPase activity of complex V (1530%) and
citrate synthase (575%) and a downregulation of the mitochon-
drial- and nuclear-encoded enzyme activities of complex I (22%)
and complex IV (78%) related to the matching control tissue
(Table 3).
One tumour tissue displayed only an elevated level of citrate
synthase (300%). As expected, no pathogenic mutation was found
in the mtDNA of this sample.
Western blot analysis of the VHL tumour suppressor
protein
The von Hippel-Lindau tumour suppressor protein (VHL) is
frequently absent in renal carcinoma tissues. A recent study has
shown that VHL deficiency is one of the factors responsible for
downregulation of the biogenesis of OXPHOS complexes in renal
carcinoma (Hervouet et al, 2005). To exclude that the altered
enzyme activities of the OXPHOS complex in the tumour tissue
with the A3243G mutation are based on the presence of the VHL
protein, we tested tumour tissues by Western blot analysis for VHL
content. In the renal carcinoma tissue harbouring the A3243G
mutation as well as in the two other renal carcinoma tissues
investigated, lack of VHL protein was observed (Figure 3).
DISCUSSION
In the present study, we evaluated the influence of mtDNA
mutations on the OXPHOS capacity of renal carcinoma tissues.
The mtDNA was more frequently mutated in renal carcinoma than
in kidney cortex tissues. This is in line with somatic mtDNA
mutations reported in a wide variety of human neoplasias (Fliss
et al, 2000; Jones et al, 2001; Nagy et al, 2002; Tan et al, 2002).
Somatic mutations in coding regions of the mtDNA in tumour
tissues are either silent or mostly nonpathogenic polymorphisms.
Only a few pathogenic mtDNA mutations have been reported
(Brown et al, 1992; Parrella et al, 2001; Lorenc et al, 2003).
However, no biochemical analysis has been performed to evaluate
the consequences of these mutations in the tumour tissues. Here,
we show the first combined genetic and biochemical analysis of
a mitochondrial A3243G mutation in a tumour tissue. The renal
carcinoma tissue with the somatic A3243G mutation showed a
compensatory upregulation of enzyme complexes, which are
only nuclear encoded. This is in clear contrast to the coordinated
downregulation of all components necessary for mitochondrial
energy metabolism, which we found in 92% of all renal carcinoma
tissues irrespective of tumour stage and progression (Meierhofer
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Figure 1 Analysis of a shift of heteroplasmy in matched tissue pairs.
Denaturating HPLC analysis of a PCR fragment (15587–16185) from case
11 at 56.01C oven temperature (A, B). Denaturating HPLC analysis
revealed a heteroplasmy of the kidney tissue of about 40% (A) and of the
corresponding renal carcinoma tissue of over 95% (B). Sequence analysis
indicates a 16092C/T heteroplasmy in the kidney tissue (C) and the
16092C mutation in the corresponding renal carcinoma (D). Denaturating
HPLC analysis of a PCR fragment (8466–8925) from case 12 at 57.81C
oven temperature (E, F). The kidney tissue shows a heteroplasmy of about
50% (E) and the corresponding carcinoma tissue of about 80% (F).
Sequence analysis revealed a 8750C/T heteroplasmy in the kidney tissue
(G) and the 8750C variation in the corresponding carcinoma tissue (H).
Y¼CþT.
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set al, 2004). However, the low activity of the partially mtDNA-
encoded complexes of the respiratory chain in the tumour tissue
with the somatic A3243G mutation will lead to similar low
oxidative capacity as in the other renal cell carcinomas. Accord-
ingly, histology and clinical progression did not differ.
The biochemical consequences of the A3243G mutation in the
renal carcinoma tissue are in agreement with the decreased activity
of the mitochondrial- and nuclear-encoded complex I and IV
reported in muscle biopsy and fibroblasts of patients with MELAS
syndrome carrying the A3243G mutation (de Vries et al, 1994;
Wilichowski et al, 1998; Pronicki et al, 2002). Our findings indicate
that the biochemical changes caused by the pathogenic A3243G
mutation are not dependent on tissue type and therefore, it seems
to be a general cellular compensatory mechanism.
The discrepancy between the normal enzyme activity of complex
II vs the decreased complex I and IV enzyme activities in the
sample with the A3243G mutation may lie partly in the fact that
the latter complexes are involved in proton pumping, whereas the
former is not.
Lack of the VHL protein and somatic alterations in the
VHL gene are found in about half of conventional renal
carcinomas (Brauch et al, 2000). Hervouet et al (2005) reported
that the transfection of the VHL gene in VHL-deficient renal
carcinoma cells increases mtDNA and respiratory chain protein
contents and permitted the cells to rely on their mitochondrial
ATP production to grow in the absence of glucose. Presence of
an intact VHL protein in the tumour tissue could have explained
the observed upregulation of the enzyme activities in the renal
carcinoma tissue with the A3243G mutation. However, the VHL
protein was not detectable in our case harboring the A3243G
mutation.
In contrast to several other studies reporting mtDNA mutations
in cancer tissues, no somatic homoplasmic mutations were
detected in the renal samples investigated here. One explanation
might be that we used sensitive DHPLC analysis with a detection
limit of heteroplasmy of down to 1% and up to 99%, respectively
(Meierhofer et al, 2005). Furthermore, contaminations of the
tumour tissues with blood and epithelial cells of vessels might
contribute to a certain degree of heteroplasmy. However, these
contaminations might also have been latent in previous studies.
Finally, because of high background in sequence analysis,
heteroplasmies of over 80% might appear as homoplasmic
mutation and therefore, high-level of heteroplasmy in this study
might be equivalent to homoplasmy in other studies (Meierhofer
et al, 2005). In accordance, the heteroplasmy in the tumour tissue
of case 12 (C8750T) is only visible in DHPLC analysis but not in
direct sequence analysis (Figure 1F and H). For the same reason,
Table 2 Gain of somatic mutations of the entire mitochodrial DNA genome in renal carcinoma tissues
Case Tumour type Grade Nucleotide position Heteroplasmy
a in tumour (%) Gene Amino acid Notes
1 Conv. RC
b 2/3 C338T o25 D-loop c
1 A1578G o25 12S rRNA d
1 G12007A o25 ND4 syn c
2 Conv. RC 3 G4584A o25 ND2 A39T d
3 Conv. RC 2 G94A 475 D-loop c
3 A7423G o25 COI E507G d
4 Conv. RC 3 T204C 25–75 D-loop c
4 A3243G 475 tRNA
LEU(UUR) MELAS
4 G1169A 475 12S rRNA d
4 C12510A 475 ND5 D58E d
5 Papillary RC 1 T2222C 25–75 16S rRNA d
6 Papillary RC 2 C1566T o25 12S rRNA d
6 T10579C o25 ND4L M37T d
7 Sarkomatoid RC 4 C16174T 25–75 D-loop c
aEstimated by denaturating HPLC analysis.
bConv.¼conventional; RC¼renal carcinoma; syn¼synonymous.
cPreviously reported polymorphism (MITOMAP database).
dNovel
mutation.
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Figure 2 Mitochondrial DNA analysis of the renal carcinoma with the
somatic A3243G mutation. Denaturating HPLC analysis of a PCR fragment
(3079–3505) of case 4 at 581C oven temperature (A–C). The kidney
tissue shows a single homoplasmic peak (A), the corresponding renal
carcinoma tissue a heteroplasmy over 90% (B) and the mixture of
denaturated and reannealed PCR product of kidney and the corresponding
tumour tissue resulted in one hetero- and homoduplex peak of the similar
height (C). Sequence analysis of the PCR product indicated the wild-type
3243A variant in the unaffected kidney tissue (D), and the 3243G mutation
in the corresponding carcinoma tissue (E), as indicated by arrows. Agarose
gel analysis of a restriction digestion of a PCR fragment (3118–3332) with
HaeIII, which specifically recognizes the 3243G mutation, and two control
sites within the PCR fragment yielding two small fragments (F): undigested
full-length PCR fragment of 215 base pairs (lane 1); kidney tissue resulting in
a 169-base pair fragment (lane 2); carcinoma tissue resulting in a weak 169-
base pair fragment of the residual wild-type 3243A variant as well as 72-
and 97-base pair fragments, indicating the 3243G mutation (lane 3); 100bp
molecular weight marker (lane 4). R¼GþA.
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slow-level heteroplasmy might be overlooked by automated
sequence analysis.
It is difficult to compare the frequency of mtDNA mutations in
different studies analysing mtDNA mutations in distinct cancer
types, because most of these studies only analysed parts of the
mitochondrial genome, mostly the D-loop. Complete sequence
analysis of the mtDNA of 10 primary ovarian carcinomas revealed
somatic mtDNA mutations in 60% of the tumour samples (Liu
et al, 2001). Another study found that 74% of breast cancer
samples had at least one somatic mtDNA mutation (Tan et al,
2002), indicating that the incidence of homoplasmic or high level
heteroplasmic somatic mutations in these tumours is higher than
in renal cell carcinoma reported here.
Mutations in the D-loop regulatory region might alter the
rate of DNA replication by modifying the binding affinity of
significant trans-activating factors. In the renal carcinomas
presented here, only four out of the 14 somatic mutations affected
the D-loop. This cannot explain the decrease of the mtDNA
content observed in the majority of renal carcinomas (Simonnet
et al, 2002; Meierhofer et al, 2004). In agreement with other
studies, either G to A or T to C transitions were observed, which
is consistent with the mutagenic spectra of oxidative damage
(Lee et al, 2004).
In half of the somatic mutations, the level of heteroplasmy was
between 1 and 25%. Phenotypic manifestation of a genetic defect of
the mtDNA occurs only if a threshold level is exceeded. Although
the phenotypic threshold depends on the type of mutation and
tissue, it has been shown that a heteroplasmy at least over 60% is
necessary to show effects on the enzyme activity of respiratory
chain complexes (Rossignol et al, 2003). Therefore, a primary role
of the low heteroplasmic mutations in downregulation of OXPHOS
activity and renal carcinogenesis is unlikely. Accumulation of
mtDNA mutations in tumours can be explained without selection
(Coller et al, 2001). Heteroplasmic mutations might have
accumulated in cancer cells by random drift of a pre-existing
heteroplasmy (Nekhaeva et al, 2002). This random drift will
also explain the observed shift of the degree of heteroplasmy of a
mixture of mutated and wild-type mtDNA already detectable in
tumour progenitor cells.
In conclusion, the low frequency as well as the low level of
heteroplasmy of the somatic mtDNA mutations in renal carcino-
mas does not indicate a major contribution of these alterations in
tumour development. Furthermore, the downregulation of the
mitochondrial energy metabolism observed in renal carcinomas
cannot be explained by the presence of mtDNA mutations. Even,
the case carrying the A3243G mutation exhibits normal tumour
histology and low overall oxidative capacity. More likely, a general
nuclear-encoded mechanism results in the adaptation of the
aerobic energy metabolism in renal carcinoma.
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